Results 151 to 160 of about 644,115 (313)

Reversing factor Xa inhibitors – clinical utility of andexanet alfa

Journal of Blood Medicine, 2017
Scott Kaatz,1 Hardik Bhansali,1 Joseph Gibbs,2 Robert Lavender,3 Charles E Mahan,4 David G Paje5 1Division of Hospital Medicine, 2Department of Internal Medicine, Henry Ford Hospital, Detroit, MI, 3Division of General Internal Medicine, University of ...
Kaatz S, Bhansali H, Gibbs J, Lavender R, Mahan CE, Paje DG   +5 more
doaj  

Inhibition of AMPKα Pathway by Podocyte GOLM1 Exacerbates Diabetic Nephrology in Mice

Advanced Science, Volume 12, Issue 37, October 6, 2025.
Podocyte Golgi membrane protein 1 interacts with epidermal growth factor receptor to inhibit peroxisome proliferator activated receptor γ, and then inactivates adenosine monophosphate activated protein kinase α pathway, which facilitates diabetes‐related inflammation, oxidative damage, apoptosis, and renal dysfunction.
Peng Xu, Kaiqiang Li, Huasong Liu, Aibo Xu, Zhewei Zhang, Yimin Yang, Xiaobo Lai, Ke Hao, Kui Fang, Zeyu Lai, Xiping Ou, Yuqun Cai, Zhen Wang, Keda Lu, Wanli Jiang   +14 more
wiley   +1 more source

Stabilizing Interfaces of All‐Ceramic Composite Cathodes for Li‐Garnet Batteries

Advanced Energy Materials, Volume 15, Issue 37, October 7, 2025.
A novel co‐firing approach enables dense, secondary‐phase‐free LiCoO₂–Li₇La₃Zr₂O₁₂ composite cathodes under high lithium and oxygen partial pressures. This strategy reduces interfacial resistance by orders of magnitude and delivers a record areal capacity of 3.48 mAh cm⁻², advancing the development of oxide‐based all‐solid‐state lithium metal batteries.
Steffen Weinmann, Hana Gobena, Lucie Quincke, Jesse J. Hinricher, Samuel Merk, Hyunwon Chu, Thorben Prein, Jennifer L.M. Rupp, Kun Joong Kim   +8 more
wiley   +1 more source

Structural Basis for Inhibition Promiscuity of Dual Specific Thrombin and Factor Xa Blood Coagulation Inhibitors [PDF]

, 2001
Herbert Nar, M. R. Bauer, Angela Schmid, Jean–Marie Stassen, Wolfgang Wienen, Henning Priepke, Iris K Kauffmann, Uwe J. Ries, Norbert Hauel   +8 more
openalex   +1 more source

Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors.

New England Journal of Medicine, 2016
Stuart J Connolly, T. Milling, J. Eikelboom, C. Michael, Gibson, J. Curnutte, A. Gold, Michele D. Bronson, Genmin Lu, P. Conley, P. Verhamme, Jeannot Schmidt, S. Middeldorp, Alexander T Cohen, J. Beyer-Westendorf, P. Albaladéjo, J. López-Sendón, S. Goodman, J. Leeds, Brian L. Wiens, Deborah M. Siegal, E. Zotova, Brandi Meeks, J. Nakamya, W. Lim, M. Crowther   +25 more
semanticscholar   +1 more source

Site‐Specific Antithrombotic Therapy: 24‐Month Outcomes of the Randomized DESyne BDS Plus Trial Using a Novel Triple‐Drug Eluting Coronary Implant With Two Anticoagulants and Sirolimus

Catheterization and Cardiovascular Interventions, Volume 106, Issue 4, Page 2770-2780, October 1, 2025.
ABSTRACT Background DESyne BDS Plus represents a novel triple drug therapy (TRx) applied on a coronary stent platform eluting the antiproliferative drug Sirolimus along with two anticoagulants (Rivaroxaban and Argatroban) to reduce the site‐specific thrombotic risk.
Stefan Verheye, Bert Ferdinande, Johan Bennett, Rodolfo Staico, Seif El‐Jack, Pim A. L. Tonino, Alexandre Abizaid, Ian Buysschaert, Douglas Scott, Madhav Menon, Gerard Wilkins, Dougal McClean, Tomas Kovarnik, Uwe Christians, Antoinette Neylon, Zlatko Mehmedbegovic, Pieter C. Smits, Marie‐Claude Morice, Mark Webster, the DESyne BDS Plus RCT Investigators   +19 more
wiley   +1 more source

The role of factor Xa inhibitors in venous thromboembolism treatment

Vascular Health and Risk Management, 2015
Katherine P Cabral,1 Jack E Ansell2 1Department of Pharmacy Practice, Albany College of Pharmacy and Health Sciences, Albany, NY, USA; 2Hofstra-North Shore/LIJ School of Medicine, Hempstead, NY, USA Abstract: Three factor Xa inhibitors have been studied
Cabral KP, Ansell JE
doaj  

A Case of an Acquired Factor V Inhibitor Triggered by Levofloxacin and Ceftazidime and Effectively Treated With Clinical Pharmacist Assistance

Clinical Case Reports, Volume 13, Issue 10, October 2025.
ABSTRACT Acquired factor V inhibitor is a rare and clinically challenging condition that can manifest across a spectrum ranging from asymptomatic laboratory abnormalities to life‐threatening hemorrhagic episodes. This case reports a patient with antibiotic‐associated AFVI, who presents asymptomatically and may be managed conservatively with close ...
Chunjuan Zhao, Weibu Chen, Xueyan Chen
wiley   +1 more source

Design of the Hydrophobic Core of Self‐Assembling Peptide Fibrils for Enhanced Neural Regeneration

Small Science, Volume 5, Issue 10, October 2025.
This study reports the design of neurosupportive peptide fibrils by systematically varying the hydrophobic core of EF‐C‐derived peptide variants. Peptides containing phenylalanine or isoleucine side chains are identified as having high aggregation propensities and performing superior in cell culture studies.
Yu‐Liang Tsai, Primiana Cavallo, Qi Lu, Jiyao Yu, Christopher P. Ender, Julian Link, Katrin Amann‐Winkel, Kristina Endres, Christopher V. Synatschke, Torsten John   +9 more
wiley   +1 more source

Quantifying Patient Reported and Documented Compliance with Adjuncts to Venous Thromboembolism Prophylaxis [PDF]

, 2017
Objectives: 1. Measure patient compliance with pharmacologic, mechanical and ambulatory prophylactic measures. 2. Evaluate for agreement between nursing documentation and patient reported compliance with mechanical and ambulatory prophylactic measures ...
Bauer, MD, Tyler M., Beck, Johanna, Cowan, MD, Scott W., Dukleska, MD, Katerina, Dworkin, Myles, Johnson, MD, MPH, Adam P., Merli, MD, Geno J, Patel, RN, Kamini D.   +7 more
core   +1 more source